May 18, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 9,987
May 19, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 9,988
May 20, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 9,987
May 21, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 37,821
May 27, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 685
May 28, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 807
May 29, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 3,523
Jun 1, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 476
Jun 3, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 500
Jun 5, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 2,640
Jun 8, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 978
Jun 16, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 310
Jun 17, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 251
Jun 18, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 1,100
Jun 26, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 17,971
Jun 29, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 250
Jul 6, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 1,000
Jul 14, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 10,041
Jul 15, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 3,610
Jul 20, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 80
Jul 22, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 165
Jul 23, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 2,669
Jul 24, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 264
Jul 29, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 181
Aug 13, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 186
Aug 14, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 127
Aug 18, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 225
Aug 21, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 112,137
Sep 1, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 378
Sep 2, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 500
Sep 16, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 100
Sep 25, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 817
Oct 1, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 5,903
Oct 5, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 378
Oct 6, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 1,700
Oct 20, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 119
Oct 22, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 500
Oct 28, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 300
Nov 5, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 277
Nov 16, 2026 ET · Open $0.00 · High $0.00 · Low $0.00 · Close $0.00 · Volume 712
Event records
Event records load after the price chart.
Split-adjusted daily prices · Price as of Nov 17, 2026, 8:44 PM ET
Initial 6M price range summary
Range
6M
First close
$0.00
Last close
$0.00
High
$0.00
Low
$0.00
Volume
239,643
Open
—Historical · Nov 16, 2026
Previous close
—Historical · Nov 16, 2026
Day range
—Historical · Nov 16, 2026
52-week range—
Volume
—Historical · Nov 16, 2026
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—
Price history
EFTR · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable
Notable price movement
Sessions where the close moved at least twice its average daily move of the prior 20 sessions (minimum 3%), or 10% or more.
$0.00−75.00%
Trading volume was 2.4 times the 30-day average, with 712 shares traded.
$0.00+300.00%
Trading volume was 0.4 times the 30-day average, with 277 shares traded.
$0.00−75.00%
Trading volume was 0.2 times the 30-day average, with 300 shares traded.
Options flow
— · Options flow not available
Q Score
—/100—
Latest available: Nov 13, 2026 · updates irregularly
Each axis is a 0 to 100 percentile rank among equities
Not scored: Equity peers
What each one means
LiquidityNot scored
Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.
ShortNot scored
Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.
SqueezeNot scored
Higher scores reflect a higher published Squeeze score within equity peers.
TrendNot scored
Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.
MomentumNot scored
Higher scores reflect stronger 63- and 126-session total returns within equity peers.
ValuationNot scored
Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.
StabilityNot scored
Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.
Insider sellSR ONE CAPITAL MANAGEMENT, LLC / SR One Capital Fund I Aggregator LP / SR ONE CAPITAL PARTNERS I, LP / SR One Co-Invest I, LLC / SR One Co-Invest I Manager, LLC / George SimeonSell$108.3KForm 4
Insider sellSR ONE CAPITAL MANAGEMENT, LLC / SR One Capital Fund I Aggregator LP / SR ONE CAPITAL PARTNERS I, LP / SR One Co-Invest I, LLC / SR One Co-Invest I Manager, LLC / George SimeonSell$261.1KForm 4
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosertib, an oral
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.